A Phase 1, Open-Label, Positron Emission Tomography Study With [18F]MNI-794 to Determine Phosphodiesterase 2A Brain Enzyme Occupancy of TAK-915 After Single-Dose Oral Administration in Healthy Subjects

Trial Profile

A Phase 1, Open-Label, Positron Emission Tomography Study With [18F]MNI-794 to Determine Phosphodiesterase 2A Brain Enzyme Occupancy of TAK-915 After Single-Dose Oral Administration in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Jul 2016

At a glance

  • Drugs TAK 915 (Primary)
  • Indications Schizophrenia
  • Focus Pharmacokinetics
  • Sponsors Takeda
  • Most Recent Events

    • 19 Jul 2016 Status changed from recruiting to completed.
    • 18 Mar 2016 Planned End Date changed from 1 Feb 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov.
    • 18 Mar 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top